Previous 10 | Next 10 |
Kiromic BioPharma press release (NASDAQ:KRBP): FY GAAP EPS of -$2.26. Cash and equivalents were $25.35M as of December 31, 2021, compared to $10.15M as of December 31, 2020. For further details see: Kiromic BioPharma GAAP EPS of -$2.26
Highlights Include Company’s Progress in the Following Areas: Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform Key Hires in Research & Development, Clinical Translational Medicine and Clinical...
Company Expects to File 2021 Form 10-K Prior to 15-day Extension Period Expiration Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) , a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMON...
San Francisco, California--(Newsfile Corp. - March 31, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now . The firm is investigating Kiromic's possible securities law violations. Visit: https://www.hbsslaw...
SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now . The firm is investigating Kiromic’s possible securities law violations. Visit: ...
SAN FRANCISCO, March 16, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now . The firm is investigating Kiromic’s possible securities law violations. Visit: ...
Kiromic BioPharma press release (NASDAQ:KRBP): Q3 GAAP EPS of -$0.40 misses by $0.14. Cash and cash equivalents were $36.16M as of September 30, 2021, compared to $10.15M as of December 31, 2020. For further details see: Kiromic BioPharma GAAP EPS of -$0.40 misses by $0.14
Quarter Updates Include Company’s Progress in the Following Areas: Expansion of DIAMOND ® AI Platform to More than 1.5 Billion Data Points Completion of InSilico Solutions, LLC Acquisition Closing of Public Offering Add...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine! It’s time for another breakdown of the biggest pre-market stock movers as we prepare for the opening bell on Wednesday! Source: f11photo/Shutterstock.com News moving stocks this morning includ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! In preparation for another busy day of trading, we’ve put together a list of the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com We’ve got ear...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...